Announcements and Notices - [Other - Business Update]

Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide

Voluntary Announcement - 
Harmoni-6 Results Published In The Lancet & 2025 Esmo
Mpfs 11.14m Vs 6.9m (Hr=0.60, P50.0001) For Ivonescimab Plus
Chemo Vs Tislelizumab Plus Chemo In 1l Advanced Sq-Nsclc

Financial Statements/ESG Information - [Interim/Half-Year Report]

2025 Interim Report

Next Day Disclosure Return

Announcements and Notices - [Placing / Issue of Shares under a General Mandate / Inside Information / Change in Shareholding]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Akeso Biopharma Inc (9926 HK)

Voluntary Announcement - Harmoni-6 Results Published In The Lancet & 2025 Esmo Mpfs 11.14m Vs 6.9m (Hr=0.60, P50.0001) For Ivonescimab Plus Chemo Vs Tislelizumab Plus Chemo In 1l Advanced Sq-Nsclc

2025 Interim Report

Next Day Disclosure Return

Completion Of Placing Of New Shares Under General Mandate And Placing Of Existing Shares

Placing Of New Shares Under General Mandate And Placing Of Existing Shares

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)